Point Roberts, WA - December 4, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research for independent investors publishes CFA commentary on Decision Diagnostics Corp. (OTCBB: DECN), by Patrick J. Murphy of Murphy Analytics LLC, a provider of sponsored research coverage on smallcap stocks.

Decision Diagnostics Corp. (OTCBB: DECN)

Patrick J. Murphy
Decision Diagnostics Corp. is developing products that offer unique solutions in medical care. The Shasta GenStrip® is an at home diagnostic for testing blood glucose designed to run on the Johnson & Johnson's (NYSE: JNJ) LifeScan LifeFirst™ OneTouch® family of meters, which are used by over 5 million people in the U.S. alone and for which JNJ estimates 97% of patients, including those with Medicare, are insured.

 

Of the products developed by DECN, the Company's Shasta GenStrip® in particular has significant potential for helping the rapidly growing diabetic population. DECN reports that the application for the Shasta GenStrip® was submitted to the FDA in December of 2010, and although the approval process typically now takes in excess of two years, DECN is now responding to a short series of follow up questions from the FDA, subsequent to recent meetings.

Select Stock Trading Data

Recent Stock Price:

$0.17

Shares Outstanding:

    

11.48 million

Float

    

8.4 million

Recent Market Cap:

    

$1.95 million

52 Week Range:

    

$0.05 - $0.65

Exchange:

    

OTCBB

Ticker:

    

DECN

URL:

    

http://www.decisiondiagnostics.com/

Data sourced from Yahoo! Finance; otcbb.com; Company filings

In terms of the overall market opportunity, a report from Research and Markets estimates that the global blood glucose monitoring market was estimated to be worth $8.9 billion in 2010 and is expected to grow 4.5% annually to reach $12.2 billion, with blood glucose test strips representing nearly 90% of the market at $10.9 billion. The report also cites International Diabetes Federation that diabetes affected 366 million people in 2011, or 8.3% of the global population, and that this is projected to increase to 9.9% of the population by 2030.

DECN also has developed a line of medical IT products for the rapidly expanding EMR/HER market. Unlike other medical information systems using standard computer terminals, Decision Diagnostics Corp. uses smart phones, which allow physicians to carry, access and update their patients' histories, medication data, and best care guidelines - all at the point of care. Decision Diagnostics Corp. is a provider of prescription drugs, home testing products for the chronically ill, a fulfillment provider of direct to patient diabetes programs, and a developer of cutting edge cell phone centric e-health products and technologies.

Patrick Murphy Bio:

Patrick J. Murphy is the owner of Murphy Analytics LLC, a provider of sponsored research coverage on smallcap stocks. Mr. Murphy has nearly 20 years of capital markets experience providing institutional investment and transaction analysis across a range of asset classes including microcap equities, commercial real estate debt and equity, municipal derivatives and public finance, venture capital, fixed income, CMBS and mortgage REIT's. In addition to his work with Murphy Analytics, Mr. Murphy also serves as a consultant to a municipal derivatives advisory firm. Mr. Murphy is an alumnus of the University of Notre Dame (1991), with an undergraduate degree in Economics, and earned a Masters Degree in Finance from St. Louis University in 1997. Mr. Murphy is a CFA Charterholder and a member of the CFA Society of St. Louis.

Patrick Murphy Disclaimer:

Readers are advised that the above article is solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. The views expressed herein are based upon the author's analysis of the issuer's public disclosures, and assumes both their accuracy and completeness. The opinions and statements included herein are based on sources (including the companies discussed and public sources) believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy, completeness or correctness. The author has not independently verified the information contained herein. This information is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. You should review a complete information package on all companies, which should include, but not be limited to, the Company's annual report, quarterly reports, press releases and all regulatory filings. The foregoing discussion contains statements which are based on current expectations, estimates and projections, and differences from such expectations, estimates and projections can be expected. The author, Patrick Murphy, was compensated $500 by InvestorIdeas.com for writing this article. Murphy does not own shares of any of the companies mentioned in this article. Mr. Murphy's research firm, Murphy Analytics, may be engaged for the provision of a research report on the Company in the future.

Decision Diagnostics Company websitehttp://www.decisiondiagnostics.com/

DECN SEC quarterly file

http://biz.yahoo.com/e/120820/decn10-q.html

More info on DECN at Investorideas.com http://www.investorideas.com/CO/DECN/

About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com

Sign up for the free investor news and stock alerts at Investorideas.com

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.

Disclosure: Investorideas.com has been compensated one hundred fifty thousand shares for news and content publication and distribution for 45 days

http://www.investorideas.com/About/Disclaimer.asp

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

800-665-0411 - Source - www.Investorideas.com

http://www.lifescan.com/about-us

http://www.onetouch.com/onetouch-diabetes-testing-supplies

http://www.pharmpro.com/News/2011/05/Animas-and-LifeScan-Strengthen-Strategic-Focus-to-Better-Serve-People-Living-with-Diabetes/

http://www.investorideas.com/CO/DECN/news/2012/11211.asp

http://www.businesswire.com/news/home/20120111006216/en/Research-Markets-Blood-Glucose-Test-Strips-Market

http://www.diabetes.org/diabetes-basics/diabetes-statistics/?loc=DropDownDB-stats

http://www.cdc.gov/obesity/data/facts.html

http://www.ncbi.nlm.nih.gov/pubmed/17893688

http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004546/

http://www.investorideas.com/CO/DECN/news/2012/11281.asp